Schedule of estimated useful lives of property, plant and equipment

The Company's property, plant, and equipment primarily consists of buildings, land, assembly equipment, molding machines, molds, office equipment, furniture, and fixtures. Depreciation and amortization are calculated using the straight-line method over the following useful lives:


Production equipment		3 to 13 years
Office furniture and equipment		3 to 10 years
Buildings		39 years
Building improvements		5 to 15 years

Schedule of disaggregated information of revenue recognized from contracts with customers and licensing fees recognized

Disaggregated information of revenue recognized from contracts with customers and licensing fees recognized are as follows:


		For the year ended December 31, 2025:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	21,082,703			1,344,293			9,779,025			30,878		$	32,236,899
North and South America sales (excluding U.S.)			3,185,850			—			1,874,848			—			5,060,698
Other international sales			641,403			25,698			288,764			12,749			968,614
Total		$	24,909,956		$	1,369,991		$	11,942,637		$	43,627		$	38,266,211


		For the year ended December 31, 2024:
					Blood									Total
					Collection			EasyPoint^®			Other			Product
Geographic Segment		Syringes			Products			Needles			Products			Sales
U.S. sales		$	19,491,747			1,259,289			8,595,794			27,315		$	29,374,145
North and South America sales (excluding U.S.)			1,895,393			96			59,040			6,240			1,960,769
Other international sales			1,242,748			166,222			293,352			12,297			1,714,619
Total		$	22,629,888		$	1,425,607		$	8,948,186		$	45,852		$	33,049,533


		For the year ended December 31, 2023:
					Blood
					Collection			EasyPoint^®			Other			Total
Geographic Segment		Syringes			Products			Needles			Products			Revenue
U.S. sales (excluding U.S. government)		$	26,119,940			1,414,783			7,031,798			33,233		$	34,599,754
North and South America sales (excluding U.S.)			5,858,726			—			—			226,440			6,085,166
Other international sales			2,176,674			511,788			216,944			6,600			2,912,006
Total		$	34,155,340		$	1,926,571		$	7,248,742		$	266,273		$	43,596,926

Schedule of diluted EPS under the treasury stock method

The potential dilution, if any, is shown on the following schedule:


		Years Ended December 31,
		2025			2024			2023
Net loss		$	(12,565,230)		$	(11,886,524)		$	(7,011,036)
Preferred stock dividend requirements			(230,444)			(230,444)			(231,946)
Loss applicable to common shareholders		$	(12,795,674)		$	(12,116,968)		$	(7,242,982)
Average common shares outstanding			29,937,159			29,937,159			29,937,159
Average common and common equivalent shares outstanding — diluted			29,937,159			29,937,159			29,937,159
Basic loss per share		$	(0.43)		$	(0.40)		$	(0.24)
Diluted loss per share		$	(0.43)		$	(0.40)		$	(0.24)